Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2022-02-02 Report Publication Anno…
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the publication of Un-Audited Financial Results for the quarter and nine months ended December 31, 2021. It mentions that the results have been published in newspapers and encloses copies of these results. The document length is short (1138 characters), and it primarily serves as an announcement of the publication of financial results rather than containing the full financial report itself. According to the 'Menu vs Meal' rule, such a document is classified as a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR).
2022-02-02 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a submission to the National Stock Exchange of India and Bombay Stock Exchange, dated February 1, 2022. It contains standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2021. The document includes detailed financial tables with income, expenses, profit before tax, tax expenses, and earnings per share. It also includes a Limited Review Report by the statutory auditors, which is typical for interim financial results. The presence of quarterly and nine-month financial data, unaudited results, and a limited review report aligns with the characteristics of an Interim / Quarterly Report. The document is about 15,000 characters long, contains substantive financial data and analysis, and is not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-02-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 60% confidence The document is a notice about the rescheduling of a conference call to discuss the Q3 financial results of Indoco Remedies Limited. It includes details about the new date and time for the call, the agenda (discussion on Q3FY22 results and future outlook), and contact information for participation. There are no actual financial statements or detailed financial data presented in the document. It is an announcement related to a conference call, not the transcript or the earnings release itself. Therefore, the document fits best as a Call Transcript (CT) precursor or invitation, but since it is only the invitation/rescheduling notice, it is not a transcript. However, given the options, the closest classification is Call Transcript (CT) as it pertains to a conference call event. Confidence is moderate due to the document being an invitation rather than the transcript itself.
2022-01-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a short notice announcing the schedule of a conference call meeting related to the discussion of Q3FY22 results and future outlook. It includes details such as date, time, dial-in numbers, and contact information for RSVP. There are no actual financial statements or substantive financial data presented in the document. It is not the earnings release itself but an announcement of the call where such results will be discussed. Therefore, it fits the category of a Call Transcript (CT) announcement or invitation rather than the transcript itself. However, since it is only the schedule and invitation, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the call schedule, not the transcript or earnings release itself.
2022-01-25 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited and Bombay Stock Exchange Limited. It references Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, and encloses a certificate from the Registrar and Share Transfer Agent for the quarter ended December 31, 2021. The document is short (1010 characters) and serves as a notification or submission of a certificate related to shareholding or depository compliance, not a full report or financial statement. There is no indication of financial results, management discussion, or other report content. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-01-06 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding the publication of a Board Meeting Notice. It mentions the notice was published in newspapers and is dated January 5, 2022. The document is short (1070 characters) and does not contain any financial data, results, or detailed reports. It is an announcement about the scheduling or publication of a board meeting notice, not the meeting materials or minutes themselves. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-01-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.